Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase NA 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Leukemia, Myeloid, Acute 55Myelodysplastic Syndromes 19Recurrence 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Leukemia, Lymphocytic, Chronic, B-Cell 13Leukemia, Myelomonocytic, Chronic 12Lymphoma, Non-Hodgkin 11Leukemia 11Multiple Myeloma 9Lymphoma, Mantle-Cell 7Hematologic Neoplasms 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Follicular 6Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myeloid 3Burkitt Lymphoma 3Neoplasms 2Neoplasm, Residual 2Myeloproliferative Disorders 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia, Prolymphocytic, T-Cell 2Leukemia, Biphenotypic, Acute 2Immunoglobulin Light-chain Amyloidosis 2Dendritic Cell Sarcoma, Interdigitating 2Waldenstrom Macroglobulinemia 1Thrombocytosis 1Thrombocythemia, Essential 1

Interventions

Dexamethasone 7daratumumab 3Peripheral Blood Stem Cell Transplantation 3Calcium Dobesilate 3venetoclax 2pomalidomide 2ixazomib 2fludarabine phosphate 2Whole-Body Irradiation 2Mycophenolic Acid 2Lenalidomide 2Cyclosporine 2Cyclophosphamide 2ethanolamine oleate 1dexamethasone acetate 1carfilzomib 1birtamimab 1belantamab mafodotin 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Thalidomide 1Sulfamethoxazole 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1Phenytoin 1Pentetic Acid 1Methotrexate 1Melphalan 1In Situ Hybridization, Fluorescence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Immunoglobulin Light-chain Amyloidosis × venetoclax × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

NCT05486481 2025-03-06

Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

University of California, San Francisco

Phase 1/2 Withdrawn
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡